Literature DB >> 18388079

Percutaneous thrombin injection for treatment of iatrogenic femoral artery pseudoaneurysms: a case for caution.

Marc-Alexander Ohlow1, Maria-Anna Secknus, Hubertus von Korn, Reginald Weiss, Bernward Lauer.   

Abstract

The case of a patient who developed a femoral artery pseudoaneurysm following cardiac catheterization is described. After 2 failed attempts of ultrasound-guided compression repair, the patient underwent percutaneous thrombin injection with, beside of complete closure of the pseudoaneurysm, a severe limb ischemia due to distal thrombin migration with consecutive clot formation finally resulting in thigh amputation of the affected leg. Indications, advantages, and disadvantages of various options for the treatment of iatrogenic femoral artery pseudoaneurysms (vascular surgery, ultrasound-guided compression, percutaneous thrombin injection, and other nonsurgical treatment modalities), as well as risk factors for distal migration of liquid thrombin after percutaneous injection, are discussed in this report.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18388079     DOI: 10.1177/0003319707304575

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  3 in total

Review 1.  Iatrogenic percutaneous vascular injuries: clinical presentation, imaging, and management.

Authors:  Benjamin H Ge; Alexander Copelan; Dominic Scola; Micah M Watts
Journal:  Semin Intervent Radiol       Date:  2015-06       Impact factor: 1.513

2.  Post-traumatic pseudoaneurysm of the thyrocervical trunk.

Authors:  Kaushal Mehta; Eric England; Josh Apgar; Jonathan Moulton; Ariyan Javadi; Robert Wissman
Journal:  Skeletal Radiol       Date:  2013-04-16       Impact factor: 2.199

3.  Percutaneous Thrombin Injection Based on Computational Fluid Dynamics of Femoral Artery Pseudoaneurysms.

Authors:  Hyoung-Ho Kim; Kyung-Wuk Kim; Changje Lee; Young Ho Choi; Min Uk Kim; Yasutaka Baba
Journal:  Korean J Radiol       Date:  2021-07-26       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.